The acceptance of the amendment by the MHRA is a positive regulatory development for TCBP, indicating progress in their clinical trial. This could lead to increased investor confidence and potentially a positive impact on TCBP's stock price in the short term. The changes to the trial, including the dose increase and shift to outpatient procedures, are likely to be viewed positively by investors as they may indicate a streamlined and potentially more efficient trial process.